Two cases of bullous pemphigoid effectively treated with oral tofacitinib
Soundos Youssef, Stephanie M. Gallitano, Lindsey A. Bordone
Abstract
Bullous pemphigoid (BP) is the most common subepidermal autoimmune blistering disease,1 chiefly affecting elderly patients in their eighth decade of life.2 BP pathogenesis is thought to be instigated by an autoantibody response toward hemidesmosomal proteins (BP180 and BP230)3 and currently has no cure. There is growing data on the positive role of oral tofacitinib, a Janus kinase inhibitor (JAKi), for the treatment of autoimmune cutaneous diseases.4,5 We herein retrospectively report 2 cases of BP seen at Columbia University Medical Center’s Dermatology clinic, and treated with 10 milligrams (mg) of off-label oral tofacitinib twice daily.
Topics & Concepts
TofacitinibMedicineBullous pemphigoidDermatologyJanus kinase inhibitorJanus kinaseAutoantibodyPemphigoidAutoimmunityAutoimmune diseaseDiseaseImmunologyInternal medicineAntibodyRheumatoid arthritisCytokineAutoimmune Bullous Skin DiseasesUrticaria and Related ConditionsCoagulation, Bradykinin, Polyphosphates, and Angioedema